PWG
CRL icon

Portside Wealth Group’s Charles River Laboratories CRL Stock Holding History

Portside Wealth Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,104
Closed -$217K – 425
2024
Q3 		$217K Sell
1,104
-155
-12% -$32.2K 0.04% 361
2024
Q2 		$260K Sell
1,259
-31
-2% -$7.02K 0.05% 294
2024
Q1 		$350K Buy
1,290
+45
+4% +$10.7K 0.06% 252
2023
Q4 		$294K Sell
1,245
-11
-0.9% -$2.16K 0.05% 268
2023
Q3 		$250K Sell
1,256
-31
-2% -$6.36K 0.05% 277
2023
Q2 		$271K Buy
+1,287
New +$256K 0.05% 274

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Portside Wealth Group's CRL Position: Q4 2024 in Review

Portside Wealth Group sold out of Charles River Laboratories (CRL) in Q4 2024, closing a stake of 1,104 shares — an estimated $217K sold.

Portside Wealth Group first reported a position in CRL in Q2 2023 and held it in 6 quarters. The position peaked at $350K in Q1 2024. 637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Portside Wealth Group reported no remaining Charles River Laboratories position as of Q4 2024 after selling out during the quarter.
  • Portside Wealth Group sold 1,104 Charles River Laboratories shares in Q4 2024, an estimated $217K.
  • Portside Wealth Group first reported a position in Charles River Laboratories in Q2 2023 and held it in 6 quarters.
  • Portside Wealth Group's Charles River Laboratories position peaked at $350K in Q1 2024.
  • 637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Portside Wealth Group's 13F filing for Q4 2024, filed 15 Jan 2025.